Kim Jeong-Whun, Tsukishiro Takashi, Johnson Jonas T, Whiteside Theresa L
University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Clin Cancer Res. 2004 Aug 1;10(15):5101-10. doi: 10.1158/1078-0432.CCR-04-0309.
Apoptosis of T lymphocytes in the circulation of patients with squamous cell carcinoma of the head and neck (SCCHN) was shown to target effector CD8+ rather than CD4+ T cells. This study evaluates the contribution of pro- and antiapoptotic components of the mitochondria-dependent pathway to apoptosis of circulating CD8+ T cells in these patients.
Blood samples were obtained from 77 patients with SCCHN and 51 normal control(s) (NC). Percentages of CD8+Annexin V+ (ANX+) and CD8+CD95+ cells, changes in mitochondrial membrane potential and levels of expression of Bcl-2, Bcl-XL, and Bax in CD8+ T lymphocytes were measured by quantitative flow cytometry.
Elevated percentages (P < 0.001) of early apo-ptotic (CD8+ANX+ CD95+) T cells in the circulation distinguish SCCHN patients from NCs but not patients with no evidence of disease (NED) from those with active disease (AD). Circulating CD8+ but not CD4+ T cells in patients were found to contain higher levels of proapoptotic Bax and antiapoptotic Bcl-XL (P < 0.01) than NC cells. The Bax/Bcl-2 ratio was elevated in CD8+ T cells of patients relative to NCs (P < 0.01), and it correlated with the percentage of ANX+CD8+ T cells (P = 0.007). The Bax/Bcl-XL ratio discriminated AD from NED patients.
Apoptosis of circulating CD8+T cells is found in SCCHN patients with AD or NED. Up-regulated Bax and Bcl-XL expression, the elevated Bax/Bcl-2 ratio and its association with ANX binding implicate the mitochondrial pathway in death of CD8+ T cells of patients with SCCHN. Understanding of molecular mechanisms of T-cell death and survival is essential for the development of more effective biotherapies for SCCHN.
头颈部鳞状细胞癌(SCCHN)患者循环系统中T淋巴细胞的凋亡显示以效应性CD8⁺而非CD4⁺T细胞为靶点。本研究评估线粒体依赖性途径的促凋亡和抗凋亡成分对这些患者循环CD8⁺T细胞凋亡的作用。
从77例SCCHN患者和51例正常对照(NC)获取血样。通过定量流式细胞术检测CD8⁺膜联蛋白V⁺(ANX⁺)和CD8⁺CD95⁺细胞的百分比、线粒体膜电位的变化以及CD8⁺T淋巴细胞中Bcl-2、Bcl-XL和Bax的表达水平。
循环系统中早期凋亡(CD8⁺ANX⁺CD95⁺)T细胞百分比升高(P < 0.001)可区分SCCHN患者与NC,但不能区分无疾病证据(NED)患者与有活动性疾病(AD)患者。发现患者循环中的CD8⁺而非CD4⁺T细胞比NC细胞含有更高水平的促凋亡Bax和抗凋亡Bcl-XL(P < 0.01)。患者CD8⁺T细胞中的Bax/Bcl-2比值相对于NC升高(P < 0.01),且与ANX⁺CD8⁺T细胞百分比相关(P = 0.007)。Bax/Bcl-XL比值可区分AD患者与NED患者。
在有AD或NED的SCCHN患者中发现循环CD8⁺T细胞凋亡。Bax和Bcl-XL表达上调、Bax/Bcl-2比值升高及其与ANX结合的关联表明线粒体途径参与SCCHN患者CD8⁺T细胞死亡。了解T细胞死亡和存活的分子机制对于开发更有效的SCCHN生物疗法至关重要。